Scinai
Scinai is a biopharmaceutical company focused on developing inflammation and immunology biological products and providing CDMO services.
Classification
Profile
Funding
Funding details not yet available.
Elevating drug development by providing inflammation and immunology biological products and comprehensive CDMO services through its Scinai Bio-services business.
Pharmaceutical and biotech companies requiring biological product development and contract manufacturing, development, and production services.
Revenue generated from the sale of inflammation and immunology biological products and fees for CDMO services via its Scinai Bio-services division.
Direct sales and corporate engagement, leveraging its public listing on NASDAQ (SCNI) for investor and partner visibility.
Information insufficient
Primary costs include R&D operations, manufacturing, quality control, GMP analytics, and executive leadership salaries.
Leadership team including CEO Amir Reichman, COO Elad Mark, and specialized heads for R&D, manufacturing, and quality control.
Developing I&I biological products, providing CDMO services, managing GMP analytics, and overseeing manufacturing and R&D operations.
Direct B2B engagement focused on long-term drug development partnerships and manufacturing service delivery.
Competes in the biopharmaceutical and CDMO sectors by offering specialized inflammation and immunology biological products and integrated development services.
Addresses the need for specialized biological product development and reliable contract manufacturing for inflammation and immunology therapies.
The dual-track model (CDMO + therapeutic pipeline) is a proven growth engine in biotech (e.g., Alnylam, Moderna pre-IPO). Scinai’s 2025 CDMO · NanoAbs technology is scientifically validated; the VHH domain has been licensed by multiple large pharma (e.g., Sanofi’s acquisition of Abl
No investors recorded yet.